Cargando…

Stabilized HIV-1 envelope glycoprotein trimers for vaccine use

PURPOSE OF REVIEW: To provide an update on the latest developments in the field of HIV-1 antibody-based soluble envelope glycoprotein (Env) trimer design for vaccine use. RECENT FINDINGS: The development of soluble native-like HIV-1 Env trimer immunogens has moved the field of antibody-based vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Medina-Ramírez, Max, Sanders, Rogier W., Sattentau, Quentin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	HIV AND NOVEL STRATEGIES FOR INDUCTION OF BROAD NEUTRALIZING ANTIBODIES FOLLOWING VACCINATION: Edited by Ralf Wagner
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389599/ https://www.ncbi.nlm.nih.gov/pubmed/28422788 http://dx.doi.org/10.1097/COH.0000000000000363

Ejemplares similares

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
por: Gardner, Matthew R., et al.
Publicado: (2017)

Lessons learned from human HIV vaccine trials
por: Pollara, Justin, et al.
Publicado: (2017)

Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms
por: Brouwer, Philip J.M., et al.
Publicado: (2019)

Chemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens
por: Schiffner, Torben, et al.
Publicado: (2015)

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens
por: Sattentau, Quentin J.
Publicado: (2013)

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model
por: Amanat, Fatima, et al.
Publicado: (2019)

Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine
por: Yao, Yanfeng, et al.
Publicado: (2019)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages
por: Guo, Li, et al.
Publicado: (2023)

Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
por: Raman, Sathya N. Thulasi, et al.
Publicado: (2023)

Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities
por: Wang, Lili, et al.
Publicado: (2023)

Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro
por: Ozorowski, Gabriel, et al.
Publicado: (2018)

Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers
por: Schorcht, Anna, et al.
Publicado: (2020)

Recovering vaccine coverage lost due to the COVID-19 pandemic()
por: Moraga-Llop, F.A., et al.
Publicado: (2020)

Adenoviral vector-based COVID-19 vaccines-associated cerebral venous sinus thromboses: Are those adverse events related to the formation of neutrophil extracellular traps?
por: Simka, Marian
Publicado: (2022)

Selection of new COVID-19 genotypes following mass vaccination: The Rotavirus model
por: Lapolla, Pierfrancesco, et al.
Publicado: (2022)

Mass vaccinations against COVID-19 through the use of technologies for the management of appointment scheduling and data of large volumes of vaccinated()
por: Rodas-Martinez, Alicia K., et al.
Publicado: (2022)

Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin
por: Ringe, Rajesh P., et al.
Publicado: (2020)

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
por: López, Pio, et al.
Publicado: (2023)

The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization
por: Schorcht, Anna, et al.
Publicado: (2022)

Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein
por: van Haaren, M. M., et al.
Publicado: (2021)

Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
por: Torrents de la Peña, Alba, et al.
Publicado: (2018)

Establishment of the 1st Chinese national standard for CA6 neutralizing antibody
por: Wang, Yiping, et al.
Publicado: (2023)

A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal
por: Chaudhary, Shipra, et al.
Publicado: (2023)

The applications of animal models in phage therapy: An update
por: Mehmood Khan, Fazal, et al.
Publicado: (2023)

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial
por: Galgani, Ilaria, et al.
Publicado: (2023)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)

Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally
por: Liao, Yun, et al.
Publicado: (2023)

Analysis and prediction of the incidence and prevalence trends of gonorrhea in China
por: Chen, Xueya, et al.
Publicado: (2023)

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
por: Patel, Sanjay S., et al.
Publicado: (2023)

Advancements in the development of nucleic acid vaccines for syphilis prevention and control
por: Li, Sijia, et al.
Publicado: (2023)

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China
por: Ma, Yuan, et al.
Publicado: (2023)

Challenges in development of vaccines directed toward antimicrobial resistant bacterial species
por: Brazzoli, Michela, et al.
Publicado: (2023)

Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics
por: Torrents de la Peña, Alba, et al.
Publicado: (2019)

Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer
por: Sliepen, Kwinten, et al.
Publicado: (2015)

Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization
por: Turner, Hannah L., et al.
Publicado: (2021)

Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization
por: Turner, Hannah L., et al.
Publicado: (2021)

The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice
por: Wegmann, Frank, et al.
Publicado: (2015)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers
por: Ringe, Rajesh P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ontpla7gq0e4hsubljjq7qii5h